3 Reasons the Market Is Down on Gilead Sciences

Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.

Brian Orelli
Brian Orelli
Apr 18, 2014 at 6:30PM
Health Care

After a solid two-year run, Gilead Sciences (NASDAQ:GILD) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie (NYSE:ABBV)and Merck (NYSE:MRK) around the corner.

In the slideshow below, you'll find three reasons investors are down on Gilead Sciences and thoughts on the biotech's future.